New research sheds light on a common link between tumor formation and Costello Syndrome, an inherited developmental disorder in which patients have cardiac defects, mild mental retardation, and face-shape abnormalities. The study published in the journal Disease Models & Mechanisms (DMM), http://dmm.biologists.org uses a zebrafish model to help explain a puzzling connection between Costello syndrome and cancer.
Costello Syndrome is one of several developmental disorders caused by mutations in a gene known as H-RAS. Additionally, mutations in H-RAS and the Ras family of genes are common in most human cancers. Thus, scientists are trying to determine how genetic mutations that activate H-RAS can cause a congenital illness as well as cancer . In this new study, Cristina Santoriello and colleagues investigate this mystery by expressing activated H-RAS in zebrafish, which are often used to study the developmental process. They found that the effect of mutant H-RAS in part depends on the timing and level of gene expression. Higher levels of H-RAS caused overabundant cell-growth, reminiscent of tumors. Furthermore, zebrafish expressing mutant H-RAS through development displayed hallmarks of the human Costello Syndrome, such as reduced body size, heart defects, and physical deformities.
This new model of Costello Syndrome can be used to learn more about this disease, particularly in regard to symptoms that worsen with age. Additionally, using this model to examine the developmental processes that control cancerous mutant H-RAS effects can potentially lead to novel cancer therapies.
Notes:
Commentary on this work will be featured in the DMM Podcast for Volume 2, Issue 1/2 of DMM. Podcasts are available via the DMM website at: http://dmm.biologists.org.
The report was written by Cristiana Santoriello, Gianluca Deflorian, Federica Pezzimenti, Luisa Lanfrancone, Fabrizio d’Adda di Fagagna and Marina Mione of the European Institute of Oncology and the FIRC Institute for Molecular Oncology Foundation in Milan, Italy, and Koichi Kawakami of the National Institute of Genetics, Mishima, Shizuoka, Japan. The report is published in the January/February issue of a new research journal, Disease Models & Mechanisms (DMM), published by The Company of Biologists, a non-profit based in Cambridge, UK.
About Disease Models & Mechanisms:
Disease Models & Mechanisms (DMM) is a new research journal publishing both primary scientific research, as well as review articles, editorials, and research highlights. The journal’s mission is to provide a forum for clinicians and scientists to discuss basic science and clinical research related to human disease, disease detection and novel therapies. DMM is published by the Company of Biologists, a non-profit organization based in Cambridge, UK.
The Company also publishes the international biology research journals Development, Journal of Cell Science, and The Journal of Experimental Biology. In addition to financing these journals, the Company provides grants to scientific societies and supports other activities including travelling fellowships for junior scientists, workshops and conferences. The world’s poorest nations receive free and unrestricted access to the Company’s journals.
Source:
Donna Perry
The Company of Biologists
Similar Posts:
- Newly Found Enzymes May Play Early Role In Cancer - Zebrafish Study Suggests New Targeted Treatment
- A Cellular Task Force To Safeguard Genome Stability
- Cyclophilin B Is A Possible New Target For Treating Breast Cancer
- In Lung Cancer, Silencing One Crucial Gene Disrupts Normal Functioning Of Genome
- Novel Glioblastoma Mouse Model Developed By Salk Researchers
Researchers have discovered two enzymes that, when combined, could be involved in the earliest stages of cancer. Manipulating these enzymes genetically might lead to targeted therapies aimed at slowing or preventing the onset of tumors. “We could conceivably reactivate a completely normal gene in a tumor cell - a gene that could prevent the growth of a tumor if reactivated,” says David Jones, Ph.
The maintenance of genome stability is crucial for protecting an organism against the onset of cancer and the study of the mechanisms controlling genome stability represents one of the most promising frontiers in cancer research. A recent study, published in Nature, now sheds light on a complex regulatory system based on sumoylation and ubiquitination, two important regulatory processes involved
Dr. Charles Clevenger and colleagues at Northwestern University have uncovered that cyclophilin B may contribute to progression in breast cancer. Their report can be found in the January 2009 issue of The American Journal of Pathology. The protein cyclophilin B affects cell division, motility, and death, all of which are altered in cancerous cells. To explore the role of cyclophilin B-mediated ge
While examining patterns of DNA modification in lung cancer, a team of international researchers has discovered what they say is a surprising new mechanism. They say that “silencing” of a single gene in lung cancer led to a general impairment in genome-wide changes in cells, contributing to cancer development and progression. In the January 1, 2009, issue of Cancer Research, a journal of the Amer
Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma - the most common and deadly brain cancer in humans - that closely resembles the development and progression of human brain tumors that arise naturally. “Mouse models of human cancer have taught us a great deal about the basic principles of cancer biology,” says Inder Verma, Ph.D., a pr